Website References

  1. Varithena® (polidocanol injectable foam) [prescribing information]. London, England; Provensis Ltd, a BTG International group company; 2014Data on file. Provensis Ltd, a BTG International group company; 2013.
  2. Eckmann DM. Polidocanol for endovenous microfoam sclerosant therapy. Expert Opin Investig Drugs. 2009;18(12):1919-1927.  
  3. O'Leary DP, Chester JF, Jones SM. Management of varicose veins according to reason for presentation. Ann R Coll Surg Engl. 1996;78(3 (Pt 1)):214-216.
  4. Darvall KA, Bate GR, Sam RC, Adam DJ, Silverman SH, Bradbury AW. Patients' expectations before and satisfaction after ultrasound guided foam sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg. 2009;38(5):642-647.
  5. Palfreyman SJ, Drewery-Carter K, Rigby K, Michaels JA, Tod AM. Varicose veins: a qualitative study to explore expectations and reasons for seeking treatment. J Clin Nurs. 2004;13(3):332-340.
  6. Tessari L, Cavezzi A, Fruilini A. Preliminary experience with new sclerosing foam in the treatment of varicose veins. Dermatol Surg. 2001;27(1):58-60.
  7. Todd KL III, Wright DI, and the VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. 2014;29(9):608-618. doi:10.1177/0268355513497709.
  8. Mason H, Baker R, Donaldson C. Understanding public preferences for prioritizing health care interventions in England: does the type of health gain matter? J Health Serv Res Policy. 2011;16(2):81-89.
  9. Lindsey B,  Campbell WB. Rationing of treatment for varicose veins and use of new treatment methods: a survey of practice in the United Kingdom. Eur J Vasc Endovasc. 2006;32(4):472.

Contact Us

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Enter security code:
 Security code


Varithena® (polidocanol injectable foam) is a prescription medicine used to treat varicose veins caused by problems with the great saphenous vein (GSV) and other related veins in the leg's GSV system. Varithena® improves symptoms related to or caused by varicose veins, and the appearance of varicose veins.


You should not be treated with Varithena® if you are allergic to polidocanol or have clots in your blood vessels.

Severe allergic reactions have been reported in people treated with liquid forms of polidocanol and some patients have died from these reactions. Varithena® is a foam made from polidocanol. A healthcare professional will observe you for signs of allergic reactions for at least 10 minutes after you are treated with Varithena®.

Tell your doctor about all of your medical conditions, including if you

  • have arterial disease (a disease of the blood vessels)
  • have reduced mobility
  • have a history of blood clots in the veins or lungs
  • have had major surgery in the past 3 months
  • have recently had a long hospital stay
  • are pregnant or have recently been pregnant

The most common side effects seen with Varithena® are leg pain or discomfort, injection site bruising or pain, and potentially serious blood clots in the leg veins. These are not all of the possible side effects of Varithena®. Tell your healthcare provider about any side effect that bothers you or that does not go away. You can also report side effects to the FDA at 1-800-FDA-1088. Varithena® is administered by your doctor. Doctors using Varithena® must be experienced in vein procedures and trained in using Varithena®.

See Full Prescribing Information for Varithena®.

Follow Us